Using Genetic Techologies in the Companion Animal Sector

Simon Brodie

November 16, 2005
CLU - Richter Hall Ahmanson Science Building

Leading edge work in genetic technologies is about to provide alternatives to current veterinary diagnostics and pet allergy treatments. A Southern California company, has received worldwide positive attention from the medical, veterinarian, and public for its developing technologies: a fast, effective and disruptive genetic based diagnostic testing process for animal pathogens; and genetically modified “lifestyle pets”, beginning with a hypoallergenic cat.

From a single saliva swab, GeneSentinel uses patented technology that identifies the DNA of a large range of viruses, bacteria and parasites in a single test (commonly referred to as a "panel"). GeneSentinel provides a level of accuracy unequalled in animal diagnostics at price that generally equals the cost of a single test. With results available in 24 hours, GeneSentinel maximizes the clinician's ability to make the correct prognosis, while reducing both the cost of treatment and suffering in the affected companion animal.

This company is also exploring the use of genetic technologies to create pets that improve the ownership experience, such as a hypoallergenic cat. In addition, this company is researching the use of genetics to develop animals that are resistant or immune to diseases for which there are no known cures or limited therapies.

Simon Brodie

Simon Brodie is an entrepreneurially focused business leader with 20+ years of international corporate development. He has successfully managed divisions of multinational corporations and has guided startup companies right through acquisition. Mr. Brodie continues to focus on revolutionary technologies that disrupt the marketplace.